Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against ...

A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

“The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

A man’s acquired hemophilia coincided with a rare liver disease, a connection that had not been reported before, per a case ...

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory ...

The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising ...

Their work highlights antibody features that could help people design better vaccines for HIV and even autoimmune diseases. "This work gives us a clearer picture of how these antibodies interact ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets ... for the exclusive worldwide rights to a pair of bispecific antibodies. HXN-1002 targets α4β7 and TL1A with ...

About HXN-1003: HXN-1003 targets TL1A and IL23, two central drivers of inflammation in various human autoimmune diseases. By simultaneously blocking both pathways, the bispecific antibody has ...